Prospective studies are need to determine whether measurement of tumor or kidney levels of TfR1 in biopsied or surgically resected specimens might assist physicians in postoperative management of nephrectomy patients, including high-risk patient identification for adjuvant therapy trials. The gene discussed is TFRC; the disease is neoplasm.